Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

GHK-Cu

Cat 2 → Pending Cat 1

Growth & Recovery · Research peptide (multiple suppliers)

Naturally occurring copper-binding tripeptide researched for wound healing, collagen synthesis, and tissue remodeling. Not FDA-approved for any indication.

About

Mechanism
Naturally occurring copper-binding tripeptide. Stimulates collagen synthesis, promotes wound healing, has anti-inflammatory and antioxidant properties. Activates tissue remodeling genes.
Half-Life
Estimated 1-2 hours
Route
subcutaneous
Frequency
Once daily

Clinical Dosing

1-3 mgonce daily

Not FDA-approved for any indication. Currently FDA Category 2 (restricted). Pending return to Category 1 availability.

Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.

Regulatory Status

FDA Category
Research peptide (FDA Category 2)
Reclassification
pending
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Pickart et al., International Journal of Molecular Sciences, 2012

DoseDurationDraw (50 mg vial in 4mL)Notes
1 mgMaintenance0.08 mL (8 units)Standard research dose

Available Vial Sizes

50 mg

50 mg vial

100 mg

100 mg vial

Citations

  1. [1]The Human Tripeptide GHK-Cu in Remodeling and Regeneration. International Journal of Molecular Sciences, 13(12), 16324-16346. Link(Reviewed: 2026-02-27)